title: Oncolytic Immunotherapy for Treatment of Cancer.
abstract: Immunotherapy entails the treatment of disease by modulation of the immune system. As detailed in the previous chapters, the different modes of achieving immune modulation are many, including the use of small/large molecules, cellular therapy, and radiation. Oncolytic viruses that can specifically attack, replicate within, and destroy tumors represent one of the most promising classes of agents for cancer immunotherapy (recently termed as oncolytic immunotherapy). The notion of oncolytic immunotherapy is considered as the way in which virus-induced tumor cell death (known as immunogenic cancer cell death (ICD)) allows the immune system to recognize tumor cells and provide long-lasting antitumor immunity. Both immune responses toward the virus and ICD together contribute toward successful antitumor efficacy. What is now becoming increasingly clear is that monotherapies, through any of the modalities detailed in this book, are neither sufficient in eradicating tumors nor in providing long-lasting antitumor immune responses and that combination therapies may deliver enhanced efficacy. After the rise of the genetic engineering era, it has been possible to engineer viruses to harbor combination-like characteristics to enhance their potency in cancer immunotherapy. This chapter provides a historical background on oncolytic virotherapy and its future application in cancer immunotherapy, especially as a combination therapy with other treatment modalities.
authors.affiliation: Innovent Biologics, Inc., 168 Dongping Street, Suzhou Industrial Park, 215123, China.
authors.forename: A
authors.initials: A
authors.lastname: Tsun
authors.affiliation: Innovent Biologics, Inc., 168 Dongping Street, Suzhou Industrial Park, 215123, China.
authors.forename: X N
authors.initials: XN
authors.lastname: Miao
authors.affiliation: Innovent Biologics, Inc., 168 Dongping Street, Suzhou Industrial Park, 215123, China.
authors.forename: C M
authors.initials: CM
authors.lastname: Wang
authors.affiliation: Innovent Biologics, Inc., 168 Dongping Street, Suzhou Industrial Park, 215123, China. michael.yu@innoventbio.com.
authors.forename: D C
authors.initials: DC
authors.lastname: Yu
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy / Q000379:methods*; D005720:Gamma Rays / Q000627:therapeutic use; D015972:Gene Expression Regulation, Neoplastic / Q000276:immunology*; D015316:Genetic Therapy; D006801:Humans; D007113:Immunity, Innate; D056747:Immunomodulation / Q000187:drug effects / Q000528:radiation effects; D007167:Immunotherapy / Q000379:methods; D009363:Neoplasm Proteins / Q000235:genetics / Q000276:immunology*; D009369:Neoplasms / Q000235:genetics / Q000276:immunology / Q000473:pathology / Q000628:therapy*; D050130:Oncolytic Virotherapy / Q000379:methods*; D050504:Oncolytic Viruses / Q000276:immunology* / Q000472:pathogenicity; D015398:Signal Transduction; D014779:Virus Replication
chemical_list: D000970:Antineoplastic Agents; D009363:Neoplasm Proteins
keywords: Combination therapy; Immuno-oncology; Oncolytic immunotherapy; Oncolytic virus